ArticleOncoimmunology2022

CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy.

Xiaofei Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.